

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

☒ **QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended **September 30, 2018**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number **0-6658**

**SCIENTIFIC INDUSTRIES, INC.**  
(Exact Name of Registrant as specified in Its Charter)

**Delaware**  
(State or other jurisdiction of incorporation or organization)

**04-2217279**  
(I.R.S. Employer Identification No.)

**80 Orville Drive, Suite 102, Bohemia, New York**  
(Address of principal executive offices)

**11716**  
(Zip Code)

**(631) 567-4700**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐  
Non-accelerated filer ☐

Accelerated filer ☐  
Smaller reporting company ☒  
Emerging Growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) Yes ☐ No ☒

The number of shares outstanding of the registrant's common stock, par value \$.05 per share ("Common Stock") as of October 31, 2018 is 1,494,112 shares.

---

# SCIENTIFIC INDUSTRIES, INC.

## Table of Contents

### **PART I - Financial Information**

<a href="#"><u>Item 1.</u></a>	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)	
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Operations	4
	Condensed Consolidated Statements of Comprehensive Income (Loss)	5
	Condensed Consolidated Statements of Cash Flows	6
	Notes to Unaudited Condensed Consolidated Financial Statements	7
<a href="#"><u>Item 2.</u></a>	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	13
<a href="#"><u>Item 4.</u></a>	CONTROLS AND PROCEDURES	14
<a href="#"><u>PART II - Other Information</u></a>		
<a href="#"><u>Item 6.</u></a>	EXHIBITS AND REPORTS ON FORM 8-K	14
<a href="#"><u>SIGNATURE</u></a>		15

# PART I – FINANCIAL INFORMATION

## Item 1. Financial Statements

### SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

#### ASSETS

	September 30, 2018	June 30, 2018
	(Unaudited)	
Current assets:		
Cash and cash equivalents	\$ 1,507,300	\$ 1,053,100
Investment securities	322,700	314,700
Trade accounts receivable, less allowance for doubtful accounts of \$11,600 at September 30, 2018 and June 30, 2018	1,190,000	1,444,100
Contract assets, current	67,100	278,200
Inventories	2,301,000	2,267,900
Prepaid expenses and other current assets	67,000	33,500
Total current assets	<u>5,455,100</u>	<u>5,391,500</u>
Property and equipment, net	185,600	199,500
Intangible assets, net	278,900	338,700
Goodwill	705,300	705,300
Contract assets, less current portion	245,400	245,400
Other assets	52,500	52,500
Deferred taxes	<u>386,600</u>	<u>392,600</u>
Total assets	<u>\$ 7,309,400</u>	<u>\$ 7,325,500</u>

#### LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:		
Accounts payable	\$ 362,600	\$ 428,000
Accrued expenses and taxes, current portion	541,900	657,700
Contract liabilities	75,900	63,800
Contingent consideration, current portion	118,000	118,000
Dividends payable	74,700	-
Notes payable	4,200	5,800
Total current liabilities	<u>1,177,300</u>	<u>1,273,300</u>
Accrued expenses, less current portion	60,000	60,000
Contingent consideration payable, less current portion	<u>290,000</u>	<u>290,000</u>
Total liabilities	<u>1,527,300</u>	<u>1,623,300</u>
Shareholders' equity:		
Common stock, \$.05 par value; authorized 7,000,000 shares; issued 1,513,914 shares, outstanding 1,494,112 shares at September 30, 2018 and June 30, 2018	75,700	75,700
Additional paid-in capital	2,554,600	2,545,900
Accumulated other comprehensive gain (loss)	(16,900)	1,200
Retained earnings	<u>3,221,100</u>	<u>3,131,800</u>
	5,834,500	5,754,600
Less common stock held in treasury at cost, 19,802 shares	<u>52,400</u>	<u>52,400</u>
Total shareholders' equity	<u>5,782,100</u>	<u>5,702,200</u>
Total liabilities and shareholders' equity	<u>\$ 7,309,400</u>	<u>\$ 7,325,500</u>

See notes to unaudited condensed consolidated financial statements.

**SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)**

	For the Three Month Period Ended September 30, 2018	For the Three Month Period Ended September 30, 2017
Revenues	\$ 2,038,600	\$ 1,280,800
Cost of revenues	<u>1,092,900</u>	<u>829,100</u>
Gross profit	<u>945,700</u>	<u>451,700</u>
Operating expenses:		
General and administrative	416,500	428,400
Selling	236,100	201,000
Research and development	<u>117,400</u>	<u>129,100</u>
Total operating expenses	<u>770,000</u>	<u>758,500</u>
Income (loss) from operations	<u>175,700</u>	<u>(306,800)</u>
Other income (expense):		
Other income, net	2,200	400
Interest expense	<u>(400)</u>	<u>(100)</u>
Total other income, net	<u>1,800</u>	<u>300</u>
Income (loss) before income tax expense (benefit)	<u>177,500</u>	<u>(306,500)</u>
Income tax expense (benefit):		
Current	29,500	(63,700)
Deferred	<u>6,000</u>	<u>(10,200)</u>
Total income tax expense (benefit)	<u>35,500</u>	<u>(73,900)</u>
Net income (loss)	<u>\$ 142,000</u>	<u>\$ (232,600)</u>
Basic earnings (loss) per common share	<u>\$ .10</u>	<u>\$ (.16)</u>
Diluted earnings (loss) per common share	<u>\$ .09</u>	<u>\$ (.16)</u>

See notes to unaudited condensed consolidated financial statements.

**SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN COMPREHENSIVE INCOME (LOSS) (UNAUDITED)**

	For the Three Month Period Ended September 30, 2018	For the Three Month Period Ended September 30, 2017
Net income (loss)	\$ 142,000	\$ (232,600)
Other comprehensive income (loss):		
Unrealized holding gain (loss)		
arising during period,		
net of tax	<u>(18,100)</u>	<u>2,600</u>
Comprehensive income (loss)	<u>\$ 123,900</u>	<u>\$ (230,000)</u>

See notes to unaudited condensed consolidated financial statements.

**SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)**

	For the Three Month Period Ended September 30, 2018	For the Three Month Period Ended September 30, 2017
Operating activities:		
Net income (loss)	\$ 142,000	\$ (232,600)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
Depreciation and amortization	75,900	77,100
Deferred income taxes	6,000	(10,200)
Stock-based compensation	8,700	6,200
Loss on sale of investments	5,000	-
Unrealized holding gain of investments	(6,400)	-
Changes in operating assets and liabilities:		
Trade accounts receivable	254,100	276,800
Contract assets, current	211,100	175,500
Inventories	(33,100)	(366,000)
Prepaid and other current assets	(33,500)	(90,500)
Accounts payable	(65,400)	237,700
Contract liabilities	12,100	17,000
Accrued expenses and taxes	(115,800)	12,600
Total adjustments	318,700	336,200
Net cash provided by operating activities	460,700	103,600
Investing activities:		
Purchase of investment securities, available for sale	(75,200)	(9,300)
Redemption of investment securities, available for sale	72,500	-
Capital expenditures	(900)	(31,500)
Purchase of other intangible assets	(1,300)	(700)
Net cash used in investing activities	(4,900)	(41,500)
Financing activities:		
Payments for contingent consideration	-	(142,700)
Principal payments on notes payable	(1,600)	(1,600)
Net cash used in financing activities	(1,600)	(144,300)
Net increase (decrease) in cash and cash equivalents	454,200	(82,200)
Cash and cash equivalents, beginning of year	1,053,100	1,025,100
Cash and cash equivalents, end of period	\$ 1,507,300	\$ 942,900
Supplemental disclosures:		
Cash paid during the period for:		
Income taxes	\$ 500	\$ 15,000
Interest	400	100

See notes to unaudited condensed consolidated financial statements.

**SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES**  
**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

General: The accompanying unaudited interim condensed consolidated financial statements are prepared pursuant to the Securities and Exchange Commission's rules and regulations for reporting on Form 10-Q. Accordingly, certain information and footnotes required by accounting principles generally accepted in the United States for complete financial statements are not included herein. The Company believes all adjustments necessary for a fair presentation of these interim statements have been included and that they are of a normal and recurring nature. These interim statements should be read in conjunction with the Company's financial statements and notes thereto, included in its Annual Report on Form 10-K, for the fiscal year ended June 30, 2018. The results for the three months ended September 30, 2018, are not necessarily an indication of the results for the full fiscal year ending June 30, 2019.

**1. Summary of Significant Accounting Policies**

***Principles of Consolidation***

The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Altamira Instruments, Inc. ("Altamira"), a Delaware corporation and wholly-owned subsidiary, and Scientific Bioprocessing, Inc. ("SBI"), a Delaware corporation and wholly-owned subsidiary, and Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary (all collectively referred to as the "Company"). All material intercompany balances and transactions have been eliminated.

***Recent Accounting Pronouncements***

In February 2016, the FASB issued ASU No. 2016-02, "Leases" (Topic 842). The FASB issued this update to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is currently evaluating the impact of the new standard.

In July 2017, the FASB issued ASU 2017-11, "*Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception*". Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is evaluating the effect that ASU 2017-11 will have on its financial statements and related disclosures.

***Adopted Accounting Pronouncements***

In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities". The update addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted only for certain portions of the ASU related to financial liabilities. The Company adopted this pronouncement during the interim period September 30, 2018, which resulted in a \$22,000 cumulative effect adjustment to retained earnings in the condensed consolidated balance sheet as of the beginning of the fiscal year of adoption.

In April 2016, the FASB issued ASU No. 2016-10, "*Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing (Topic 606)*". In March 2016, the FASB issued ASU No. 2016-08, "Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (Topic 606)". These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, "Revenue from Contracts with Customers". The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations; evaluating distinct performance obligations; treatment of shipping and handling costs; and determining whether an entity's promise to grant a license provides a customer with either a right to use an entity's intellectual property or a right to access an entity's intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The Company adopted the provisions of these pronouncements on July 1, 2018, using the modified retrospective approach. Revenue from the Company's sales continue to generally be recognized when products are shipped (i.e. point in time). As such, the adoption of ASU 2016-10 had no material impact to the Company's financial position or results of operations; however, the Company has now presented the disclosures required by this new standard, refer to Note 2.

In August 2016, the FASB issued ASU 2016-15, "*Classification of Certain Cash Receipts and Cash Payments*". This update provides guidance on how to record eight specific cash flow issues. This update is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted and a retrospective transition method to each period should be presented. The adoption of this ASU had no impact on the Company's consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18, "*Statement of Cash Flows (Topic 230)*", requiring that the statement of cash flows explain the change in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. This guidance is effective for fiscal years, and interim reporting periods therein, beginning after December 15, 2017 with early adoption permitted. The provisions of this guidance are to be applied using a retrospective approach which requires application of the guidance for all periods presented. The adoption of this ASU had no impact on the Company's consolidated financial statements.





## **Reclassification**

Trade accounts receivable, current of \$67,100 and \$278,200, and trade accounts receivable, long term of \$245,400 for both periods were reclassified to contract assets, current; and contract assets, less current portion, respectively, on the balance sheet as of September 30, and June 30, 2018. Customer advances were reclassified to contract liabilities as of September 30, and June 30, 2018.

## **2. Revenue**

The Company's revenues are comprised of product sales (Benchtop Laboratory Equipment Operations) as well as products and related services such as installation and training as is customary for its customers of the Catalyst Research Instruments Operations. In addition the Company's Bioprocessing Systems Operations' revenues are comprised of royalty revenues. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract (either implicit or explicit) by transferring the promised product or service to its customer either when (or as) its customer obtains control of the product or service. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract's transaction price is allocated to each distinct performance obligation. The majority of the Company's contracts have a single performance obligation, as the promise to transfer products or services is not separately identifiable from other promises in the contract and, therefore, not distinct. For contracts with multiple performance obligations, the Company allocates the contract's transaction price to each performance obligation using the Company's best estimate of standalone selling price for each distinct product or service in the contract, which is generally based on an observable price.

Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or providing services. As such, revenue is recorded net of returns, allowances, customer discounts, and incentives. Revenue from the Bioprocessing Systems Operations are recognized over time based on Management's judgment and estimates.

## **3. Segment Information and Concentrations**

The Company views its operations as three segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales ("Benchtop Laboratory Equipment Operations"), the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct basis ("Catalyst Research Instruments Operations") and the design and marketing of bioprocessing systems and products and related royalty income ("Bioprocessing Systems").

Segment information is reported as follows:

	<b><u>Benchtop Laboratory Equipment</u></b>	<b><u>Catalyst Research Instruments</u></b>	<b><u>Bioprocessing Systems</u></b>	<b><u>Corporate And Other</u></b>	<b><u>Consolidated</u></b>
Three Months Ended September 30, 2018:					
Revenues	\$ 1,691,900	\$ 217,500	\$ 129,200	\$ -	\$ 2,038,600
Foreign Sales	635,700	142,300	-	-	778,000
Income (Loss) From Operations	175,400	(62,900)	63,200	-	175,700
Assets	4,633,500	1,343,100	623,500	709,300	7,309,400
Long-Lived Asset Expenditures	2,200	-	-	-	2,200
Depreciation and Amortization	66,300	200	9,400	-	75,900

	<u>Benchtop Laboratory Equipment</u>	<u>Catalyst Research Instruments</u>	<u>Bioprocessing Systems</u>	<u>Corporate And Other</u>	<u>Consolidated</u>
--	--	--	----------------------------------	--------------------------------	---------------------

Three Months Ended September 30, 2017:

Revenues	\$ 1,199,400	\$ 28,700	\$ 52,700	\$ -	\$ 1,280,800
Foreign Sales	502,300	6,400	-	-	508,700
Loss From Operations	(93,900)	(184,100)	(28,800)	-	(306,800)
Assets	4,041,800	1,425,400	437,000	822,700	6,726,900
Long-Lived Asset Expenditures	32,200	-	-	-	32,200
Depreciation and Amortization	64,900	2,800	9,400	-	77,100

Approximately 49% and 46% of net sales of benchtop laboratory equipment for the three month periods ended September 30, 2018 and 2017, respectively, were derived from the Company's main product, the Vortex-Genie 2 mixer, excluding accessories.

For the three months ended September 30, 2018 and 2017, respectively, three customers accounted in the aggregate for approximately 23% and 22% of net sales of the Benchtop Laboratory Equipment Operations (19% and 21% of the Company's total revenues). Sales of catalyst research instruments generally comprise a few very large orders averaging approximately \$50,000 per order to a limited number of customers, who differ from order to order. Sales to three customers during the three months ended September 30, 2018 accounted for approximately 83% of the Catalyst Research Instrument Operations' revenues and 9% of the Company's total revenues. There was no significant customer sale during the three months ended September 30, 2017.

#### **4. Fair Value of Financial Instruments**

The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements do not include transaction costs.

The accounting guidance also expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are described below:

Level 1 - Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 - Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Level 3 - Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.

In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.

The fair value of the contingent consideration obligations are based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following tables.

The following tables set forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis at September 30, 2018 and June 30, 2018 according to the valuation techniques the Company used to determine their fair values:

	Fair Value at September 30, 2018	Fair Value Measurements Using Inputs Considered as		
		Level 1	Level 2	Level 3
Assets:				
Cash and cash equivalents	\$ 1,507,300	\$ 1,507,300	\$ -	\$ -
Available for sale securities	322,700	322,700	-	-
Total	\$ 1,830,000	\$ 1,830,000	\$ -	\$ -
Liabilities:				
Contingent consideration	\$ 408,000	\$ -	\$ -	\$ 408,000

	Fair Value at June 30, 2018	Fair Value Measurements Using Inputs Considered as		
		Level 1	Level 2	Level 3
Assets:				
Cash and cash equivalents	\$ 1,053,100	\$ 1,053,100	\$ -	\$ -
Available for sale securities	314,700	314,700	-	-
Total	\$ 1,367,800	\$ 1,367,800	\$ -	\$ -
Liabilities:				
Contingent consideration	\$ 408,000	\$ -	\$ -	\$ 408,000

The following table sets forth an analysis of changes during the three months ended September 30, 2018 and 2017 in Level 3 financial liabilities of the Company:

	2018	2017
Beginning balance	\$ 408,000	\$ 297,000
Payments	-	(142,700)
Ending balance	\$ 408,000	\$ 154,300

Investments in marketable securities classified as available-for-sale by security type at September 30, 2018 and June 30, 2018 consisted of the following:

	Cost	Fair Value	Unrealized Holding Gain (Loss)
At September 30, 2018:			
Available for sale:			
Equity securities	\$ 48,500	\$ 76,800	\$ 28,300
Mutual funds	262,800	245,900	(16,900)
	\$ 311,300	\$ 322,700	\$ 11,400

	<u>Cost</u>	<u>Fair Value</u>	<u>Unrealized Holding Gain (Loss)</u>
At June 30, 2018:			
Available for sale:			
Equity securities	\$ 45,700	\$ 67,800	\$ 22,100
Mutual funds	267,800	246,900	(20,900)
	<u>\$ 313,500</u>	<u>\$ 314,700</u>	<u>\$ 1,200</u>

## 5. Inventories

	<u>September 30, 2018</u>	<u>June 30, 2018</u>
Raw materials	\$ 1,312,700	\$ 1,488,000
Work-in-process	425,900	352,700
Finished goods	562,400	427,200
	<u>\$ 2,301,000</u>	<u>\$ 2,267,900</u>

## 6. Goodwill and Other Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company's acquisitions. Goodwill amounted to \$705,300 at September 30, 2018 and June 30, 2018, all of which is expected to be deductible for tax purposes.

The components of other intangible assets are as follows:

	<u>Useful Lives</u>	<u>Cost</u>	<u>Accumulated Amortization</u>	<u>Net</u>
At September 30, 2018:				
Technology, trademarks	5/10 yrs.	\$ 662,800	\$ 631,500	\$ 31,300
Trade names	6 yrs.	140,000	106,900	33,100
Websites	5 yrs.	210,000	192,500	17,500
Customer relationships	9/10 yrs.	357,000	298,100	58,900
Sublicense agreements	10 yrs.	294,000	202,100	91,900
Non-compete agreements	5 yrs.	384,000	361,500	22,500
IPR&D	3 yrs.	110,000	110,000	-
Other intangible assets	5 yrs.	199,300	175,600	23,700
		<u>\$ 2,357,100</u>	<u>\$ 2,078,200</u>	<u>\$ 278,900</u>

	<u>Useful Lives</u>	<u>Cost</u>	<u>Accumulated Amortization</u>	<u>Net</u>
At June 30, 2018:				
Technology, trademarks	5/10 yrs.	\$ 662,800	\$ 613,400	\$ 49,400
Trade names	6 yrs.	140,000	101,100	38,900
Websites	5 yrs.	210,000	182,000	28,000
Customer relationships	9/10 yrs.	357,000	294,800	62,200
Sublicense agreements	10 yrs.	294,000	194,800	99,200
Non-compete agreements	5 yrs.	384,000	348,000	36,000
IPR&D	3 yrs.	110,000	110,000	-
Other intangible assets	5 yrs.	198,100	173,100	25,000
		<u>\$ 2,355,900</u>	<u>\$ 2,017,200</u>	<u>\$ 338,700</u>

Total amortization expense was \$61,000 and \$61,100 for the three months ended September 30, 2018 and 2017, respectively. As of September 30, 2018, estimated future amortization expense related to intangible assets is \$125,900 for the remainder of the fiscal year ending June 30, 2019, \$66,400 for fiscal 2020, \$49,100 for fiscal 2021, \$26,100 for fiscal 2022, \$9,800 for fiscal 2023, and \$1,600 thereafter.

## 7. Income (Loss) Per Common Share

Income (Loss) per common share data was computed as follows:

	<b>For the Three Months Ended September 30, 2018</b>	<b>For the Three Months Ended September 30, 2017</b>
Net income (loss)	\$ 142,000	\$ (232,600)
Weighted average common shares outstanding	1,494,112	1,494,112
Effect of dilutive securities	3,897	-
Weighted average dilutive common shares outstanding	1,498,009	1,494,112
Basic earnings (loss) per common share	\$ .10	\$ (.16)
Diluted earnings (loss) per common share	\$ .09	\$ (.16)

Approximately 92,000 and 82,000 shares of the Company's common stock issuable upon the exercise of outstanding options were excluded from the calculation of diluted earnings per common share for the three months ended September 30, 2018 and 2017, respectively, because the effect would be anti-dilutive.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

**Forward-Looking statements.** *Certain statements contained in this report are not based on historical facts, but are forward-looking statements that are based upon various assumptions about future conditions. Actual events in the future could differ materially from those described in the forward-looking information. Numerous unknown factors and future events could cause such differences, including but not limited to, product demand, market acceptance, success of marketing strategy, success of expansion efforts, impact of competition, adverse economic conditions, and other factors affecting the Company's business that are beyond the Company's control, which are discussed elsewhere in this report. Consequently, no forward-looking statement can be guaranteed. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. This Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company's financial statements and the related notes included elsewhere in this report.*

**Overview.** The Company reflected income before tax expense of \$177,500 for the three months ended September 30, 2018 compared to a loss before income tax benefit of \$306,500 for the three months ended September 30, 2017, primarily the result of increased revenues across all business segments. The results reflected total non-cash amounts for depreciation and amortization of \$75,900 and \$77,100 for the three months ended September 30, 2018 and 2017, respectively.

**Results of Operations.** Net revenues for the three months ended September 30, 2018 increased \$757,800 (59.2%) to \$2,038,600 from \$1,280,800 for the three months ended September 30, 2017, reflecting an increase of \$492,500 (41.1%) in net sales of benchtop laboratory equipment. The benchtop laboratory equipment sales reflected \$425,300 of Torbal brand product sales for the three months ended September 30, 2018, compared to \$304,200 in the three months ended September 30, 2017 as a result of continued growth in sales of the new force gauges product line. Sales of catalyst research instruments increased by \$188,800 to \$217,500 for the three months ended September 30, 2018 compared to \$28,700 for the three months ended September 30, 2017 because there were no large orders shipped during the prior year period. As of September 30, 2018, the order backlog for catalyst research instruments was \$329,400, all of which is expected to be shipped during the fiscal year ending June 30, 2019, compared to \$323,900 as of September 30, 2017. Revenues derived from the Bioprocessing Systems Operations which comprise primarily of net royalties accrued from sublicenses increased by \$76,500 (145.2%) to \$129,200 for the three months ended September 30, 2018 compared to \$52,700 for the three months ended September 30, 2017.

The gross profit percentage for the three months ended September 30, 2018 was 46.4% compared to 35.3% for the three months ended September 30, 2017. The current period gross margin reflected increased gross profit margin percentage for the Benchtop Laboratory Operations as a result of higher sales and lower overhead costs. The gross profit margin percentage for catalyst research instruments was higher for the current period compared to the same period last year because the prior year period was negatively impacted by fixed overhead on significantly lower sales.

General and administrative expenses for the three months ended September 30, 2018 amounted to \$416,500 compared to \$428,400 for the three months ended September 30, 2017 due to various minor decreases in expenses for the Bioprocessing Systems Operations and the Catalyst Research Instruments Operations.

Selling expenses for the three months ended September 30, 2018 increased \$35,100 (17.5%) to \$236,100 from \$201,000 for the three months ended September 30, 2017 primarily due to increased sales and marketing activities by the Benchtop Laboratory Equipment Operations.

Research and development expenses decreased by \$11,700 (9.1%) to \$117,400 for the three months ended September 30, 2018 compared to \$129,100 for the three months ended September 30, 2017, primarily because of reduced new product development activities in the current year period for benchtop laboratory equipment.

Total other income was \$1,800 for the three months ended September 30, 2018 compared to \$300 for the three months ended September 30, 2017, due primarily to unrealized holding gains on equity securities.

The Company reflected income tax expense of \$35,500 for the three months ended September 30, 2018 compared to a tax benefit of \$73,900 for the three months ended September 30, 2017, primarily due to the income generated during the three months ended September 30, 2018.

As a result of the foregoing, the Company recorded net income of \$142,000 for the three months ended September 30, 2018 compared to a net loss of \$232,600 for the three months ended September 30, 2017.

**Liquidity and Capital Resources.** Cash and cash equivalents increased by \$454,200 to \$1,507,300 as of September 30, 2018 from \$1,053,100 as of June 30, 2018.

Net cash provided by operating activities was \$460,700 for the three months ended September 30, 2018 compared to \$103,600 used during the three months ended September 30, 2017, primarily as a result of the income for the current year period. Net cash used in investing activities was \$4,900 for the three months ended September 30, 2018 compared to \$41,500 used during the three months ended September 30, 2017 principally due to new capital equipment purchased during the prior year period by the Benchtop Laboratory Equipment Operations. The Company used \$1,600 in financing activities in the three months ended September 30, 2018 compared to \$144,300 in the three months ended September 30, 2017 due to the contingent consideration paid in the prior year period.

The Company's working capital increased by \$159,600 to \$4,277,800 as of September 30, 2018 compared to \$4,118,200, as of June 30, 2018 due to the income generated during the period.

The Company has a Demand Line of Credit through December 2018 with First National Bank of Pennsylvania which provides for borrowings of up to \$300,000 for regular working capital needs, bearing interest at prime, currently 5.25%. Advances on the line, are secured by a pledge of the Company's assets including inventory, accounts, chattel paper, equipment and general intangibles of the Company. As of September 30, 2018 no borrowings were outstanding under such line.

Management believes that the Company will be able to meet its cash flow needs during the 12 months ending September 30, 2019 from its available financial resources including the lines of credit, its cash and investment securities, and operations.

#### Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report, based on an evaluation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), the Chief Executive and Chief Financial Officer of the Company has concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in its Exchange Act reports is recorded, processed, summarized and reported within the applicable time periods specified by the SEC's rules and forms. The Company also concluded that information required to be disclosed in such reports is accumulated and communicated to the Company's management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

As a result of our adoption of the new revenue standard (Topic 606), we implemented controls to ensure adequate evaluation of contracts and assessment of the impact of the new accounting standard related to revenue recognition on our financial statements to facilitate its adoption on July 1, 2018. There were no significant changes to our internal control over financial reporting due to the adoption of the new standard, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f) during the period covered by this Quarterly Report or in other factors that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

## PART II – OTHER INFORMATION

#### Item 6. Exhibits and Reports on Form 8-K

Exhibit Number	Description
<a href="#">31.1</a>	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
<a href="#">32.1</a>	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Reports on Form 8-K:

Report dated September 28, 2018 reporting under item 8.01

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SCIENTIFIC INDUSTRIES, INC.  
(Registrant)

Date: November 13, 2018

/s/ Helena R. Santos

Helena R. Santos  
President, Chief Executive Officer, Treasurer  
Chief Financial and Principal Accounting Officer